Sherlock Biosciences Acquires Sense Biodetection Advancing Crispr-Based Diagnostics For Consumers
Acquiring Company
Sherlock Biosciences
Acquired Company
Sense Biodetection
BostonBostonBiotechnologyHealthcareData And AnalyticsHealth CareScience And EngineeringHealth CareDescription
Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point of need, today announced the acquisition of Sense Biodetection (Sense), a global molecular diagnostics innovator. The acquisition accelerates Sherlock's go-to-market strategy by adding Sense's VerosTM instrument-free rapid molecular test platform and manufacturing capabilities, enabling the vision of highly accurate and affordable diagnostics that can be used anytime, anywhere. Terms of the acquisition are not being disclosed.
Quick answer
Sherlock Biosciences is acquiring Sense Biodetection, announced February 1, 2023. Sherlock Biosciences is based in Boston, Massachusetts, United States.
- How much did Sherlock Biosciences pay for Sense Biodetection?
- The deal value was not disclosed.
- What does Sherlock Biosciences do?
- Sherlock Biosciences is developing products that will empower people to access answers and have more control over their health decisions.
- Where are Sherlock Biosciences and Sense Biodetection based?
- Sherlock Biosciences is based in Boston, Massachusetts, United States. Sense Biodetection is based in Boston, Massachusetts, United States.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Data And Analytics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Merck Completes Tender Offer To Acquire Imago Biosciences, Inc. (January 11, 2023)
- Rhythm Pharmaceuticals Announces Acquisition Of Xinvento B.V. And Portfolio Of Investigational Therapeutics (February 27, 2023)
- Clarapath Acquires Crosscope And Combines Tissue Processing Robotics With Ai Powered Digital Pathology For Building The Lab Of The Future (February 27, 2023)
- Kymanox Acquires Eu Based Anteris Medical And Anteris Helvetia (February 2, 2023)
- Shockwave Medical Announces Agreement To Acquire Neovasc (January 17, 2023)
- Shockwave Medical To Acquire Neovasc (January 17, 2023)
Who to call at Sherlock Biosciences, and when
When Sherlock Biosciences changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Sherlock Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sherlock Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sherlock Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sherlock Biosciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Sense Biodetection?
Sense Biodetection was acquired by Sherlock Biosciences, based in Boston. The deal was reported on February 1, 2023. Sherlock Biosciences is developing products that will empower people to access answers and have more control over their health decisions. Sherlock Biosciences is privately held and operates in Biotechnology.
When did Sherlock Biosciences acquire Sense Biodetection?
Sherlock Biosciences's acquisition of Sense Biodetection was reported on February 1, 2023. Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point of need, today announced the acquisition of Sense Biodetection (Sense), a global molecular diagnostics innovator. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Sense Biodetection do?
It is privately held, operating in Health Care, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.